Skip to main content

Editorial label review

Alloy side effects: breast tenderness

Primary formulary: Estradiol (oral and patch) + oral micronized progesterone; oxybutynin ER for vasomotor symptoms

Quick answer

Breast tenderness shows up on the FDA labels for the active ingredients Alloy prescribes — Estradiol (oral and patch) + oral micronized progesterone. This page walks through the labelled frequency ranges, what to watch for, and when to call your clinician.

What Alloy prescribes and why it matters for breast tenderness

Alloy prescribes FDA-approved bioidentical estradiol and oral micronized progesterone, plus oxybutynin ER as a non-hormonal option for vasomotor symptoms. Because Alloy prescribes FDA-approved active ingredients, the labelled adverse-reaction tables from those medications describe the frequencies you should expect. Breast tenderness is the single most frequent labelled reaction across all four brands.

Common label-level side effects

Sourced from Section 6 (Adverse Reactions) of each FDA-approved PIL.

  • Breast pain / mastalgia is the #1 most commonly reported adverse reaction across estradiol-progestin combination PILs (Section 6 tables), 10–45%
  • Estradiol PIL Section 5.2 references breast cancer risk from the WHI trial in the boxed warning
  • Prometrium PIL Section 6.1 lists breast tenderness at 8%

Serious label-level warnings

Drawn from Section 5 (Warnings and Precautions) of the FDA-approved PILs — including the estradiol boxed warning where applicable.

  • New breast lump, unilateral pain, or nipple discharge — estradiol PIL Section 5.2 requires prompt breast-cancer workup
  • Breast pain with skin dimpling or redness — urgent evaluation for inflammatory breast cancer independent of HRT

When to contact your clinician

Call your clinician promptly for any new breast lump, unilateral pain, nipple discharge, or skin change — the estradiol PIL boxed warning treats these as urgent.

Call 911 if you develop chest pain, one-sided weakness, sudden severe headache, vision or speech change, or shortness of breath — per the estradiol PIL boxed warning for cardiovascular events.

What to ask your provider

  • “Which SKU in the Alloy formulary am I on, and what is its labelled frequency for breast tenderness?”
  • “Is my breast tendernesslikely a labelled adverse reaction, or something separate that needs its own workup?”
  • “Would a different delivery route (patch vs. pill, oral vs. transdermal) change my expected frequency?”
  • “What is the plan if breast tendernessdoes not settle within 2–3 cycles?”

Frequently asked questions

How often does breast tenderness happen on Alloy?
Alloy's primary regimen — Estradiol (oral and patch) + oral micronized progesterone; oxybutynin ER for vasomotor symptoms — carries the FDA-labelled adverse-reaction frequencies for breast tenderness described on this page. Ranges vary from < 1% to 45% depending on the specific active ingredient and delivery route. See the sources block for the exact PIL tables.
When should I stop Alloy because of breast tenderness?
Talk to your clinician immediately if you meet any of the "when to contact" criteria on this page — most estradiol PIL Section 5 warnings require prompt reassessment. Do not stop hormone therapy without medical input; abrupt discontinuation can trigger rebound symptoms.
Is breast tenderness on the FDA label for Alloy's medications?
Breast tenderness is the single most frequent labelled reaction across all four brands.
Is breast tenderness caused by menopause itself?
Breast tenderness can appear during the menopause transition for reasons unrelated to hormone therapy. Our /does-menopause-cause/breast-tenderness explainer covers what the underlying biology is and how clinicians disentangle the transition from the treatment.

Sources

  1. FDAFDA-approved label — Estrace (estradiol) via DailyMed
  2. FDAFDA-approved label — Vivelle-Dot (estradiol transdermal) via DailyMed
  3. FDAFDA-approved label — Prometrium (micronized progesterone) via DailyMed